Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

NCT07221734 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

632

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced (Unresectable or Metastatic) Melanoma

Interventions

DRUG: MB11 (Proposed Nivolumab Biosimilar)
DRUG: EU-Opdivo®
DRUG: US- sourced Opdivo®

Sponsor

mAbxience Research S.L.